Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20748504 | 0.86 | KDM4C (0.49) | KDM4CKDRADORA2AASIC3NTRK1 | |
| SCHEMBL28427582 | 0.77 | ASIC3 (0.53) | KDRMAPKAPK2ASIC3MAP4K4TAAR1 | |
| SCHEMBL18573407 | 0.75 | ASIC3 (0.67) | MAPKAPK2ADORA2AASIC3MAP4K4TAAR1 | |
| SCHEMBL15690747 | 0.75 | ASIC3 (0.67) | MAPKAPK2ADORA2AASIC3MAP4K4TAAR1 | |
| SCHEMBL20748703 | 0.74 | KDR (0.56) | KDM4CKDRMAPKAPK2NTRK1CYP3A4 | |
| SCHEMBL1399681 | 0.73 | KDM4E (0.50) | KDM4CASIC3TAAR1CYP3A4TDP1 | |
| SCHEMBL5522367 | 0.73 | HDAC1 (0.48) | CDK5CDK5R1ADORA2ARIPK1ASIC3 | |
| SCHEMBL18745801 | 0.73 | AAK1 (0.50) | MAPKAPK2ASIC3NTRK1MAP4K4PRKCZ | |
| SCHEMBL18745799 | 0.73 | AAK1 (0.50) | MAPKAPK2ASIC3NTRK1MAP4K4PRKCZ | |
| SCHEMBL16139800 | 0.71 | KDM4C (0.57) | KDM4CKDRMAPKAPK2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473501-B1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2473501-B1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9725433-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725433-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725433-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170066738-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066738-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066738-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9475801-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475801-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20140100212-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8614234-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130065880-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065880-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065880-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| EP-2473501-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | Allergan, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011028995-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110053905-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053905-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053905-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065880-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ABL1, ERBB2, LCK | KDM4C 2656/4885KDR 111/4885MAPKAPK2 112/4885 |
| US-20110053905-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ABL1, ERBB2, LCK | KDM4C 2656/4885KDR 111/4885MAPKAPK2 112/4885 |
| US-20170066738-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ABL1, ERBB2, LCK | KDM4C 2656/4885KDR 111/4885MAPKAPK2 112/4885 |
| US-20140100212-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ABL1, ERBB2, LCK | KDM4C 2656/4885KDR 111/4885MAPKAPK2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.